MYCO-001 Smoking Cessation Clinical Trial Moves Forward Following Conditional IRB Approval Company Advances IP Portfolio With New Patent Applications Covering Novel Molecule Families DENVER, March 31, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and…


Previous articleEntheon Biomedical Announces Expanded Psychedelics Genetic Test Panel & New Clinical Research Platform
Next articlePT306 – Dr. Devon Christie – Vital Psychedelic Conversations